JPRN-jRCT2033210696招募中1 期
Phase I/II Study of Gene Therapy for Parkinson's disease
akajima Takeshi0 个研究点目标入组 12 人开始时间: 2022年3月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Patients diagnosed with Parkinson's disease by MDS Clinical Diagnostic Criteria for Parkinson's Disease.
- •-Patients aged 40 to 75 years at the time of obtaining informed consent.
- •-Patients onset of an illness> 35 years of age.
- •-Patients who have received L-dopa for at least 5 years.
- •-Patients whose severity of Hoehn & Yahr in the OFF state at the time of informed consent was IV.
- •-Patients with a baseline total MDS-UPDRS-III score (OFF) of 30 to 100.
- •-Patients who have a clear response to L-dopa and have improved MDS-UPDRS-III by at least 16 points at baseline ON and OFF.
- •-Untolerable motor complications in patients with a total score of at least 4 on MDS-UPDRS-IV at baseline (motor fluctuations) who fail to respond satisfactorily to appropriate drug therapy.
- •-Patients who can undergo stereotactic brain surgery.
- •-Patients who do not need dosage changes for the Parkinson's Disease treatment for at least 8 weeks, prior to the start of the study substance administration.
排除标准
- •-Patients with a history of cerebrovascular disease, exposure to antipsychotics or toxins, encephalitis, symptoms such as progressive supranuclear palsy or cerebellar symptoms, pyramidal signs, autonomic signs, dementia, hallucinations or delusions, or MRI findings such as lachner infarction or atrophy of the midbrain tegment, pons and cerebellum suggesting secondary or atypical parkinsonism.
- •-Patients who have already undergone stereotactic neurosurgery (pallidal coagulation, thalamic coagulation, deep brain stimulation) and MR-guided focused ultrasound therapy for Parkinson's disease.
- •-Patients with a Mini-Mental State Examination (MMSE) score of 20 or less or with a diagnosis of dementia.
- •-Patients with a history of schizophrenia or affective disorders.
- •-Patients with apparent vascular diseases, including cerebrovascular disorders.
- •-Patients with neoplastic disease of the central nervous system, clinically evident neurological disease (e.g., age-inappropriate, obvious brain atrophy).
- •-Patients with a concomitant malignancy or a history of other malignancies other than previously treated skin cancers within 5 years before obtaining informed consent.
- •-Patients with uncontrolled hypertension.
- •-Patients with coagulopathy or who require antithrombotic therapy.
- •-Patients with clinically prominent evidence of immunodeficiency who require immunosuppressant treatments excluding steroid therapy.
- •-Patients with a score of 10 or more on the Geriatric Depression Scale-short form (GDS-S) or 5 or more on antidepressants.
- •-Patients who cannot undergo MRI.
- •-Individuals who wish to have children, but do not cryopreserve sperm or eggs prior to administration of the investigational product and use them to obtain children.
- •-Patients with a history of convulsive seizures within 3 years, those taking antiepileptic drugs, or those with abnormal electroencephalograms showing epileptic abnormalities.
- •-Patients with the following complications that are hard to manage.
- •1.Patients with severe renal disorders of the magnitude of both the serum creatinine levels of > 2.0 mg/dl and BUN>25 mg/dl.
- •2.Patients with severe hepatic disorders of the magnitude of either AST/GOT or ALT/GPT is above 2.5 folds of the upper limit of the normal levels.
- •3.Patients with diabetes of the magnitude of both >200 mg/dl casual or postprandial blood glucose levels and >9% HbA1c.
研究者
相似试验
尚未招募
1 期
A Clinical Study for the Treatment of Parkinson's Disease with Integrated Shi Shi Tonifying Kidney Pill and Xingnao Kaiqiao AcupunctureParkinson's diseaseITMCTR1900002280ShenZhen JinFangZhenLue Technology Ltd. Co.
进行中（未招募）
1 期
Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector - EBGraftThe trial aims to treat the recessive dystrophic epidermolysis bullosa (RDEB) by grafting one to three subjects with RDEB with autologous COL7A1-modified skin equivalents, using SIN-RV encoding COL7A1 cDNA.MedDRA version: 20.0 Level: LLT Classification code 10074980 Term: Epidermolysis bullosa aquisita System Organ Class: 100000004858EUCTR2016-002790-35-FRINSERM3
招募中
1 期
Multi-Center, Open Label Gene Therapy Study of RP-A501 in Male Patients with Danon DiseaseCTIS2023-506480-34-00Rocket Pharmaceuticals Inc.12
已完成
2 期
Phase II trial of treatment based on gene profiling diagnosis using next generation sequencing for carcinoma of unknown primary sitentreated Carcinoma of Unknown Primary SiteJPRN-UMIN000016794Ministry of Health, Labour and Welfare scientific research Nakagawa squad110
已完成
不适用
Early treatment of idiopathic Parkinson's disease with dopaminergic agonist piribedil in monotherapy. A two-year randomised, parallel, placebo-controlled study in idiopathic Parkinsonian de novo patientsParkinson's diseaseISRCTN36646813Institut de Recherches Internationales Servier (France)400